Hoarding disorder (HD) is characterized by difficulty discarding personal possessions due to significant emotional distress when parting with personal items. This leads to the accumulation of excessive clutter which compromises the normal use of living spaces. In addition to emotional distress, individuals with HD experience significant impairment in physical health. One study found an 11-fold increase in stroke risk, a 10-fold increase in cancer risk, and a 7-fold increase in cardiovascular disease in individuals with HD relative to a general population comparison group. Patients with HD are also more likely to experience obesity and metabolic diseases such as diabetes. The short-term goal of the proposed study is to determine whether a brief exercise intervention improves discarding-related distress and brain-derived neurotropic factor (BDNF) in individuals with HD relative to a relaxation control condition. Preliminary evidence suggests that BDNF may be associated with greater body mass index and more severe HD symptoms in patients with HD. BDNF is a well-studied growth factor which is involved in neuronal transmission, plasticity, and survival of many neuron systems that have been implicated in psychiatric disorders, including serotonin, glutamate, and dopamine. BDNF has been proposed as a mechanism of exercise interventions for psychiatric disorders, as even one session of exercise has been shown to increase BDNF levels. This study represents an initial first step towards the long-term goal of improving current treatments for HD. This is important because although current cognitive-behavioral treatments (CBT) are effective, only 35% of patients who receive these treatments actually benefit from them. In the proposed pilot study, the investigators will test whether 30 minutes of moderate-intensity exercise reduces the distress associated with discarding and increases BDNF levels in individuals with HD relative to a relaxation control. The investigators will recruit 22 individuals with a primary diagnosis of HD. They will be randomly assigned to exercise or control. Following the intervention, the investigators will assess BDNF via serum. Participants will complete a standardized discarding task which consists of sorting and discarding personal possessions. The central hypothesis is that those in the exercise condition will demonstrate lower distress during the discarding task and greater BDNF levels as compared to those in the relaxation control condition. Should the hypothesis be confirmed, the investigators will be well poised to conduct large-scale clinical trials testing exercise interventions as adjunctive or alternative treatments to standard CBT.

开始日期2024-10-01

申办/合作机构

Hartford Hospital

[+1]

NCT06484621 / Not yet recruitingN/AIIT

Using Acceptance and Commitment Therapy to Promote Autonomous Motivation for Increased Physical Activity and Improved Weight Loss Maintenance in Bariatric Surgery Patients: A Randomized Trial

The goal of this clinical trial is to learn if a psychological intervention can increase regular physical activity to help prevent weight regain after metabolic bariatric surgery in adults. The main questions it aims to answer are:
1. Does the psychological intervention increase physical activity?
2. Does the psychological intervention prevent weight regain?
3. Does the psychological intervention increase internal motivation for physical activity and acceptance of the discomfort that can come with physical activity?
Researchers will compare the psychological intervention to an educational intervention to see if the psychological intervention works to increase physical activity and prevent weight regain after metabolic bariatric surgery.
Participants will:
* Complete 12 months of either the psychological or control intervention. This includes attending education and counseling workshops with a small group of participants and completing brief homework assignments and individual telephone calls with a counselor.
* Wear a device to measure physical activity, use an electronic scale to measure body weight, and complete questionnaires at home on five separate occasions over an 18-month period

开始日期2024-08-01

申办/合作机构

Hartford Hospital

[+1]

NCT06481436 / RecruitingN/AIIT

Use of Artificial Intelligence by Patients for Understanding of Diagnosis of Urogynecologic Conditions and Its Role in Treatment Decisions

The goal of this clinical trial is to learn about how Urogynecology patients use Artificial Intelligence (AI) Chatbots like ChatGPT, and how it affects healthcare decision making. The main question[s] it aims to answer are:
* How does the AI Chatbot affect participants' understanding of diagnoses and participant satisfaction with a urogynecology consultation?
* How accurate is the chatbot-provided diagnosis and counseling information? Participants will be asked to use the ChatGPT chatbot and ask it questions about the main problem the participant is seeing the doctor for, and will also be asked to fill out some questionnaires.
Researchers will compare using the Chatbot before the visit, after the visit, or not at all to see if the way participants understand the information changes based on timing of use.

开始日期2024-07-22

申办/合作机构

Hartford Hospital

[+1]

100 项与 Hartford Hospital 相关的临床结果

登录后查看更多信息

0 项与 Hartford Hospital 相关的专利（医药）

登录后查看更多信息

2,861

项与 Hartford Hospital 相关的文献（医药）

2024-11-01·ASAIO Journal

One Pump for Two Hearts: Using an Impella 5.5 Micro-Axial Pump in Peripartum Cardiogenic Shock

Article

作者: Dilip, Anum ; Badr, Mai ; Mai, Xingchen ; Bell, Jennifer ; Pillai, Ashwin A.

Cardiogenic shock (CS) occurs infrequently in pregnancy and has a high mortality rate. Medical treatment options are few, with limited evidence of efficacy. Temporary mechanical circulatory supports (tMCS) may play a key role in addressing this therapeutic lacuna. We report successfully managing second-trimester CS using an Impella 5.5 micro-axial pump. Our patient presented in the second-trimester with CS. Hemodynamic parameters indicated biventricular dysfunction (low cardiac index, low pulmonary artery pulsatility index). She received diuresis and inotropic support to optimize her fluid status and cardiac function. However, failure to improve to the point where she would be able to tolerate the hemodynamic stresses of labor despite optimizing medical therapy prompted consideration of tMCS. The Impella 5.5 was chosen for its higher output (to maximize fetal perfusion), relative longevity, and lower hemolysis rates compared to other devices. It was used to support her from gestational weeks 28–30 and through the delivery. Support was continued for 4 weeks postpartum to allow for any potential cardiac recovery. Hope unrealized, a workup for destination therapy was initiated. Patient preference and high panel reactive antibodies informed the decision to pursue destination left ventricular assist device (LVAD) therapy. After a 3 month neonatal intensive care unit (NICU) stay, mother and baby were successfully discharged home.

2024-07-01·Journal of Shoulder and Elbow Surgery

Liposomal bupivacaine provides superior pain control compared to bupivacaine with adjuvants in interscalene block for total shoulder replacement: a prospective double-blinded, randomized controlled trial

Article

作者: Kainkaryam, Pranjali ; Blaine, Theodore ; Nagarkatti, Durgesh ; Finkel, Kevin J ; Takata, Edmund T ; Walker, Aseel ; Staff, Ilene ; Nissen, Carl ; Maffeo-Mitchell, Carla L ; Sposito, Jennifer ; Shearier, Emily

INTRODUCTIONOptimal pain control methods after total shoulder arthroplasty (TSA) achieve reduced opioid consumption, shortened hospital stay, and improved patient satisfaction in addition to adequate analgesia. Interscalene brachial plexus block is the gold standard for TSA, yet it typically does not provide pain relief lasting beyond 24 hours. Liposomal bupivacaine (LB) purportedly provides prolonged analgesia, yet it has been minimally explored for interscalene block, and it is significantly more expensive than standard bupivacaine.METHODSThis is a prospective, 2-arm, double-blinded randomized controlled trial. Subjects presenting for anatomic or reverse TSA were randomized in a 1:1 ratio to receive interscalene brachial plexus block with either LB plus bupivacaine (LBB group) or bupivacaine plus dexamethasone and epinephrine (BDE group). The primary outcome was 120-hour postoperative opioid consumption. Secondary outcomes were pain scores up to 96 hours postoperatively, pain control satisfaction, complications, level of distress from block numbness, and hospital stay.RESULTSNinety patients, 45 per group, were included in the intention-to-treat analysis and randomized. Because of withdrawal of consent and loss to follow-up, 40 in each group completed enrollment through postoperative day 60. Total 120-hour postoperative opioid consumption was similar between groups (P = .127), with no differences within 24- or 48-hour time intervals. Postoperative pain scores at 24-48 hours, 48-72 hours, 72-96 hours, and day 60 were significantly lower for the LBB group.DISCUSSIONLB interscalene brachial plexus block before total shoulder arthroplasty did not reduce 120-hour postoperative opioid consumption but significantly reduced postoperative pain between 24 and 96 hours and at postoperative day 60.

2024-07-01·The American Journal of Emergency Medicine

Association of biliary distention with a diagnosis of acute cholecystitis

Article

作者: Herbst, Meghan Kelly ; Lotterman, Seth ; Cannata, David ; Anslip, Abeid ; Herbst, Timothy ; She, Trent ; Chin, Kyle A

BACKGROUNDGallbladder distention has been described in radiology literature but its value on point-of-care ultrasound (PoCUS) performed by emergency physicians is unclear. We sought to determine the test characteristics of gallbladder distention on PoCUS for cholecystitis (acute or chronic), and secondarily whether distention was associated with an obstructing stone-in-neck (SIN), acute cholecystitis on subsequent pathology report, and longer cholecystectomy operative times.METHODSThis was a dual-site retrospective cohort study of all Emergency Department (ED) patients that underwent diagnostic biliary PoCUS and were subsequently admitted from 11/1/2020 to 10/31/2022. Patients with pregnancy, liver failure, ascites, hepatobiliary cancer, prior cholecystectomy, or known cholecystitis were excluded. Gallbladder distention was defined as a width ≥4 cm or a length ≥10 cm. Saved ultrasound images were reviewed by three independent reviewers who obtained measurements during the review. Test characteristics, Cohen's kappa (κ), and strength of association between distention and our variables (acute cholecystitis on pathology report and SIN on PoCUS) were calculated using a Chi Square analysis, where intervention (cholecystectomy, percutaneous cholecystostomy, or intravenous antibiotics) was used as the reference standard for AC. A one-tail two sample t-test was calculated for mean operative times.RESULTSOf 280 admitted patients who underwent ED biliary PoCUS, 53 were excluded, and 227 were analyzed. Of the 227 patients, 113 (49.8%) had cholecystitis according to our reference standard, and 68 (30.0%) had distention on PoCUS: 32 distended by both width and length, 16 distended by width alone, and 20 distended by length alone. Agreement between investigators was substantial for width (κ 0.630) and length (κ 0.676). Distention was 85.09% (95% CI 77.20-91.07%) specific and 45.1% (95% CI 35.8-54.8%) sensitive for cholecystitis. There was an association between distention and SIN; odds ratio (OR) 2.76 (95% CI 1.54-4.97). Distention of both length and width was associated with acute over chronic cholecystitis; OR 4.32 (95% CI 1.42-13.14). Among patients with acute cholecystitis, mean operative times were 114 min in patients with distention and 89 min in patients without distention (p = 0.03).CONCLUSIONGallbladder distention on PoCUS was specific for cholecystitis (acute or chronic), and associated with SIN, acute cholecystitis on subsequent pathology report, and longer cholecystectomy operative times. Measurement of gallbladder dimensions as part of the assessment of cholecystitis may be advantageous.

项与 Hartford Hospital 相关的新闻（医药）

2024-10-15

·BioSpace

Innoviva Specialty Therapeutics to Present New Clinical Data From Its Development Pipeline and Broad Commercial Portfolio at IDWeek 2024

WALTHAM, Mass.--(BUSINESS WIRE)-- Innoviva Specialty Therapeutics, Inc. , a biotechnology company focused on delivering innovative therapies in critical care and infectious diseases, announced today the presentation of data from three clinical abstracts and two oral presentations on the company’s pipeline and Commercial portfolio during IDWeek 2024 , October 16-19, 2024, in Los Angeles, CA. “Our clinical program continues to provide important findings from recent sub-analyses that add meaningful new insights for healthcare professionals managing difficult-to-treat and antimicrobial-resistant pathogens,” said David Altarac, MD, Chief Medical Officer at Innoviva Specialty Therapeutics. “We are pleased with the progress of our development product zoliflodacin, which recently completed the pivotal phase 3 trial conducted with our partner the Global Antibiotics Research Development Partnership. If approved, zoliflodacin could lead to the first new oral antibiotic to treat gonorrhea in decades.” IDWeek 2024 Clinical Presentations Oral Presentation Addressing a growing global threat through a novel public-private development partnership David Altarac, MD, Chief Medical Officer, Innoviva Specialty Therapeutics Friday, October 18, 2024 8:00 am – 9:00 am PT Petree C Oral Presentation Activity of Sulbactam-durlobactam and Standard-of-Care Antibiotics against Acinetobacter baumannii-calcoaceticus complex isolates acquired from Hospitalized Patients in the United States (2023 – 2024) Tomefa E. Asempa, PharmD, Hartford Hospital Saturday, October 19, 2024 10:54-11:06 am PT Room 403A Poster #P-1103 In Vitro Activity of Zoliflodacin Against Baseline Neisseria gonorrhoeae Isolates from US Participants in a Global Phase 3 Randomized Controlled Trial Sarah McLeod, PhD, Innoviva Specialty Therapeutics Friday, October 18, 2024 12:15-1:30 pm PT, Hall J&K Poster #P-1251 Pharmacometric Analyses to Support Dose Selection of Zoliflodacin, a First-in-Class Oral Antibiotic Being Developed for the Treatment of Uncomplicated Gonorrhea Sujata M. Bhavnani, MD, Institute for Clinical Pharmacodynamics Friday, October 18, 2024 12:15-1:30 pm PT, Hall J&K Time Poster# P-1532 Surveillance of Eravacycline Against CLINICAL Pathogens, including Resistant Isolates, Collected Worldwide from Multiple Infection Sites During 2018-2022 Kristie Zappas, PharmD, Innoviva Specialty Therapeutics Friday, October 18, 2024 12:15-1:30 pm PT, Halls JK About Innoviva Specialty Therapeutics Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc., is focused on delivering innovative therapies in critical care and infectious disease. Innoviva Specialty Therapeutics’ products, through its affiliate, La Jolla Pharmaceutical Company, include GIAPREZA ® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock, and XERAVA ® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva Specialty Therapeutics’ product, through its affiliate, Entasis Therapeutics Inc., include XACDURO ® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex ( Acinetobacter ). For more information about Innoviva Specialty Therapeutics, please visit here . Contacts Media Contact : David Patti Innoviva Corporate Communications David.patti@inva.com 908.421.5971

临床3期上市批准合格传染病产品

2024-09-18

·PRNewswire

The Inner Circle acknowledges, Patrick M. Tamim, MD as a Pinnacle Life Member

PANAMA CITY, Fla., Sept. 18, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Patrick Tamim is acknowledged as a Pinnacle Life Member for his contributions to the Vascular Surgery Field. Continue Reading Patrick M. Tamim, MD Dr. Tamim attended Southern Methodist University where he earned a Bachelor of Science in Biology and Chemistry. He continued his education at the University of Texas Southwestern Medical School where he earned a Medical Degree; completed a general surgical residency at Henry Ford Hospital in Detroit and Abbington Hospital in Pennsylvania; and finished a one-year critical care fellowship at Henry Ford Hospital in Detroit. He capped his scholarship with a fellowship in vascular surgery at Hartford Hospital in Connecticut. Dual board-certified in vascular surgery by the American Board of Surgery, the doctor explained that the ABS is an independent, non-profit organization located in Philadelphia, Pennsylvania, founded for the purpose of certifying surgeons who have met a defined standard of education, training, and knowledge. Among his many responsibilities and skills, the doctor provides treatment for carotid disease; aortic aneurysms; and peripheral artery disease surgery. He is an expert in aortic aneurysm; carotid endarterectomy; deep vein thrombosis; dialysis; access surgery; peripheral vascular diseases; peripheral artery disease; spider vein removal; stroke; and varicose veins. Dr. Tamim explained that vascular surgery is a surgical subspecialty in which diseases of the vascular system, including the arteries, veins, and lymphatic circulation, are managed by medical therapy; treated with minimally invasive catheter procedures; and surgical reconstruction. Vascular surgeons, like the doctor, also diagnose, treat, and manage conditions in the arteries and veins, also called the blood vessels, and treat a range of health problems, from spider and varicose veins to life-threatening aneurysms, and can help patients manage chronic conditions throughout their lives. The doctor is affiliated with Bay Medical Sacred Heart and Gulf Coast Regional Medical Center where he has worked for 13 years in private practice locally in the Panama City Florida area serving Bay and surrounding counties. During his 23-year career, Dr. Tamim has received many accolades including the Patients Choice Award (2018, 2017, 2016, 2014, 2013, 2011, 2010, 2009, 2008); Compassionate Doctor Recognition (2018, 2017, 2016, 2014, 2013, 2011, 2010); Top 10 Doctors in the State (2014); and On-Time Doctor Award (2018, 2017, 2016) and is associated with the Society for Vascular Surgery and Emerald Coast Medical Association. Also a civic-minded professional, Dr. Tamim participates in a lecture series through the Council on Aging at his local hospital and speaks multiple languages, including English, French, and Arabic. When considering his extraordinary success, the doctor asserts that his philosophy to treat patients as if they are members of his own family has been a critical piece of his achievements. When he is not actively serving his patients, Dr. Tamim enjoys reading the Journal of Vascular Surgery and traveling to Lebanon and Greece. The doctor would like to dedicate this honor to his father, Marwan Tamim, MD, for all his inspiration and also to his mentors, David Drezner, MD; Phillip Allmendinger, MD; and Mary Windels, MD. For more information, please visit his website at . Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

高管变更

2024-09-10

·PRNewswire

Zavation Medical Products, LLC announces launch of Varisync® ALIF System

FLOWOOD, Miss., Sept. 10, 2024 /PRNewswire/ -- Zavation Medical Products, LLC ("Zavation"), an innovator in spinal device technology, proudly announces the launch of its latest product—the Varisync® ALIF System. Engineered to streamline ALIF procedures, the Varisync system offers customization and efficiency with two spacer fixation options: anchors and screws. Continue Reading Varisync® ALIF with Screws Varisync® ALIF with Anchors Dr. Hanbing Zhou, MD Innovative Features: The Zavation Varisync ALIF System provides unique anchor fixation in fewer operative steps than traditional screw fixation methods and through a less invasive surgical corridor. Its advanced instrumentation allows for the simultaneous deployment of three pre-loaded anchors through a small, protected working corridor no wider than the smallest width Varisync ALIF cage. This innovative anchor fixation method serves as a valuable alternative to traditional screw fixation, particularly in challenging surgical scenarios where screw instrumentation angulation is impeded by patient anatomy, such as when the sacral slope limits access to certain lumbar spine levels. Clinical Feedback : Dr. Hanbing Zhou, MD, a fellowship-trained orthopedic spine surgeon practicing at the Bone & Joint Institute at Hartford Hospital in Hartford, CT, utilized the Varisync ALIF System. This inaugural case took place in early August 2024. Dr. Zhou noted, "The Varisync ALIF System significantly reduces procedural complexity with its new anchor-based fixation. Its innovative design and efficient deployment make it a game-changer in ALIF procedures. In addition, the 3D Printed Mimetic Metal technology's porous design provides conduits for osteointegration". Patented Mimetic Metal® Technology: The Zavation Varisync ALIF System incorporates patented Mimetic Metal® cage technology in the F3D-Z Varisync ALIF spacers. This advanced technology is designed to emulate natural bone with a directional lattice architecture and trabecular pores. In-vitro studies have demonstrated that Mimetic Metal significantly increases osteoblast activity compared to machined solid titanium, PEEK, and HA-PEEK. Additionally, in-vivo studies have shown remarkable bony in-growth and on-growth in both cortical and cancellous bone*. Versatile Spacers: The system's spacers come in three standard footprints: 24x30, 26x35, and 28x40, with heights ranging from 11mm to 17mm and angles of 8 and 15 degrees. Taller height and hyperlordotic options (20 and 25 degrees) are also available within the system, catering to a wide range of surgical needs and patient anatomies. *Data on file, pre-clinical data may not be representative of clinical results. Contact Zavation for more information on Zavation's Varisync ALIF System. Indications for Use: The Zavation Varisync ALIF System is an anterior interbody fusion device indicated for use in patients with degenerative disc disease (DDD) at one or two contiguous levels from L2 to S 1. DDD is defined as back pain of discogenic origin with degeneration of the disc confirmed by history and radiographic studies. These patients should be skeletally mature and have had six months of non-operative treatment. These DDD patients may also have up to Grade I spondylolisthesis at the involved level(s). The interior of the spacer component of the Zavation Varisync ALIF System is to be filled with autogenous bone graft material. The Zavation Varisync ALIF System spacer and plate assembly are an integrated fusion device intended for standalone use when used with screws. When used with anchors only the recessed plate may be used, and the assembly is intended for use with additional supplemental fixation that has been cleared by the FDA for use in the lumbar spine. Hyperlordotic interbody devices (>20 degrees) must be used with supplemental fixation (e.g. posterior fixation) that has been cleared by the FDA for the use in the lumbar spine. About Zavation Medical Products, LLC: Based in Flowood, MS, Zavation designs, engineers, and manufactures a portfolio of spinal hardware and biologics covering key areas including cervical, thoracolumbar, interbody fusion, interventional spine, and minimally invasive surgery. Founded in 2012, Zavation has experienced exceptional growth and created a national network of numerous distributors across the United States. The Company has commercialized over 25 product families since inception. Zavation operates a newly constructed 75,000 square foot vertically integrated facility in Flowood, MS. To learn more information about Zavation and the Company's suite of products, visit . SOURCE Zavation Medical Products, LLC.